# US 2020/0002334 A1 · Inhibitors of (alpha-v)(beta-6) integrin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002334 A1
- Document ID: US20200002334A1
- Status: Published application
- Kind: A1
- Application number: 16/489,646
- Filed: 2018-02-27
- Published: 2020-01-02
- Earliest claimed: 2017-02-28
- Assignees: Morphic Therapeutic, Inc.
- Applicants: Morphic Therapeutic, Inc.
- Inventors: Bryce A. Harrison; Matthew G. Bursavich; Aleksey I. Gerasyuto; Kristopher N. Hahn; Kyle D. Konze; Fu-Yang Lin; Blaise S. Lippa; Alexey A. Lugovskoy; Bruce N. Rogers; Mats A. Svensson; Dawn M. Troast
- Web page: https://patentgrep.com/patent/US20200002334A1

## CPC

- C07D 471/04: Ortho-condensed systems
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

## Claims

### Claim 1

A compound represented by formula (I):
A-B—C (I)
wherein:
A is
B is absent, alkylene, -alkylene-(O); -alkylene-N(R)C(O)—, -alkylene-(heterocyclyl)-C(O)—, -alkylene-C(O)N(R)—, -alkylene-C(O)—, -alkylene-N(R)—, -alkylene-N(R)C(O)N(R)—, -alkylene-N(R)SO2—, -alkylene-(aryl)-, -alkylene-(heterocyclyl)-, alkylene-(heterocyclyl)-alkylene, -aryl-alkylene-N(R)C(O)—; -aryl-C(O)N(R)—, -aryl-N(R)C(O)—, -(heterocyclyl)-alkylene-, -heterocyclyl-alkylene-N(R)C(O)—; -heterocyclyl-C(O)N(R)—, —O-heterocyclyl-; -alkylene-O—; -heterocyclyl-C(O)—; cycloalkylene; or cycloalkylene-O—;
C is
R is H, alkyl, or aryl;
R1 is independently H, alkyl, halide, alkoxy, CF3, OH, NO2, —N(H)R, or NH2;
R2 is H, alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cycloalkyl, -alkylene-alkoxy, alkoxy, —OH, -alkylene-aryl, heterocycloalkyl, —N(R)C(O)R4, —N(R)SO2R4—, —N(R)-aryl, or —N(R)-heteroaryl;
R3 is independently alkyl, halide, alkoxy, CF3, OH, NO2, or NH2;
R4 is alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkylene-heterocyclyl, -alkylene-N(R)C(O)R5, or -alkylene-N(R)—SO2Me;
R5 is alkyl, or cycloalkyl;
R6 is H, or alkyl;
X is C(Rc) or N;
Rc is H, alkyl, aryl, OH, or halide;
Rd is H, or (C1-C6)alkyl;
a is independently 0, or 1; and
b is 0, 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R is H or Me.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein at least one instance of R1 is alkyl, halide, alkoxy, CF3, OH, —N(H)R, or NH2.

### Claim 4 (depends on 3)

The compound of claim 3, wherein R1 is alkyl, or halide.

### Claim 5 (depends on 1, 2)

The compound of claim 1 or 2, wherein all instances of R1 are H.

### Claim 6 (depends on 1, 2)

The compound of claim 1 or 2, wherein
A is

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein B is absent, or represents (C1-C6)alkylene, —(C1-C6)alkylene-N(R)—C(O)—, —(C1-C6)alkylene-N(R)—, —(C1-C6)alkylene-O—, or —(C1-C6)alkylene-C(O)—.

### Claim 8 (depends on 7)

The compound of claim 7, wherein B is absent or selected from the group consisting of:
R is H, Me or Ph;
m is 0, 1, 2, or 3;
n is 1, 2, or 3; and
p is 1, 2, 3, 4, 5, or 6.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein X is C(Rc).

### Claim 10 (depends on 9)

The compound of claim 9, wherein Rc is H.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein X is N.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein at least one instance of a is 0.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, wherein at least one instance of a is 1.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any one of claims 1-13, wherein b is 0.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any one of claims 1-13, wherein b is 1, or 2.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any one of claims 1-13, and 15, wherein R3 is independently alkyl, halide, alkoxy, or NH2;

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein R6 is H.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, wherein R6 is Me.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-8 and 11-16, wherein C is selected from the group consisting of:

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, wherein R2 is H, alkyl, aryl, heteroaryl, hydroxyl, or alkoxy.

### Claim 21 (depends on 20)

The compound of claim 20, wherein R2 is substituted or unsubstituted phenyl.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, wherein R2 is —N(H)C(O)R4, —N(R)SO2R4—, —N(H)-aryl, or —N(H)-heteroaryl.

### Claim 23 (depends on 22)

The compound of claim 22, wherein R2 is —N(H)-2-pyridinyl, or —N(H)-2,4-pyrimidinyl.

### Claim 24 (depends on 22)

The compound of claim 22, wherein R2 is —N(H)C(O)Me.

### Claim 25 (depends on 22)

The compound of claim 22, wherein
R4 is Me,
and
Y is H, F, or Cl.

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 27 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 28 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 29 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 30 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 31 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of:

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A pharmaceutical composition, comprising a compound of any one of claims 1-31; and a pharmaceutically acceptable excipient.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A method of treating a disease or condition selected from the group consisting of idiopathic pulmonary fibrosis, diabetic nephropathy, focal segmental glomerulosclerosis, chronic kidney disease, nonalcoholic steatohepatitis, primary biliary cholangitis, primary sclerosing cholangitis, solid tumors, hematological tumors, organ transplant, Alport syndrome, interstitial lung disease, radiation-induced fibrosis, bleomycin-induced fibrosis, asbestos-induced fibrosis, flu-induced fibrosis, coagulation-induced fibrosis, vascular injury-induced fibrosis, aortic stenosis, and cardiac fibrosis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-31.

### Claim 34 (depends on 33)

The method of claim 33, wherein the disease or condition is a solid tumor.

### Claim 35 (depends on 34)

The method of claim 34, wherein the solid tumor is selected from the group consisting of Ewing's sarcoma, rhabdomyosarcoma, osteosarcoma, myelosarcoma, chondrosarcoma, liposarcoma, leiomyosarcoma, soft tissue sarcoma, non-small cell lung cancer, small cell lung cancer, bronchus cancer, prostate cancer, breast cancer, pancreatic cancer, gastrointestinal cancer, colon cancer, rectum cancer, colon carcinoma, colorectal adenoma, thyroid cancer, liver cancer, intrahepatic bile duct cancer, hepatocellular cancer, adrenal gland cancer, stomach cancer, gastric cancer, glioma (e.g., adult, childhood brain stem, childhood cerebral astrocytoma, childhood visual pathway and hypothalamic), glioblastoma, endometrial cancer, melanoma, kidney cancer, renal pelvis cancer, urinary bladder cancer, uterine corpus, uterine cervical cancer, vaginal cancer, ovarian cancer, multiple myeloma, esophageal cancer, brain cancer (e.g., brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma), lip and oral cavity and pharynx, larynx, small intestine, melanoma, villous colon adenoma, a neoplasia, a neoplasia of epithelial character, lymphomas (e.g., AIDS-related, Burkitt's, cutaneous T-cell, Hodgkin, non-Hodgkin, and primary central nervous system), a mammary carcinoma, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, tumor diseases, including solid tumors, a tumor of the neck or head, polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, Waldenstrom's macroglobulinemia, adrenocortical carcinoma, AIDS-related cancers, childhood cerebellar astrocytoma, childhood cerebellar astrocytoma, basal cell carcinoma, extrahepatic bile duct cancer, malignant fibrous histiocytoma bone cancer, bronchial adenomas/carcinoids, carcinoid tumor, gastrointestinal carcinoid tumor, primary central nervous system, cerebellar astrocytoma, childhood cancers, ependymoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, intraocular melanoma eye cancer, retinoblastoma eye cancer, gallbladder cancer, gastrointestinal carcinoid tumor, germ cell tumors (e.g., extracranial, extragonadal, and ovarian), gestational trophoblastic tumor, hepatocellular cancer, hypopharyngeal cancer, hypothalamic and visual pathway glioma, islet cell carcinoma (endocrine pancreas), laryngeal cancer, malignant fibroushistiocytoma of bone/osteosarcoma, medulloblastoma, mesothelioma, metastatic squamous neck cancer with occult primary, multiple endocrine neoplasia syndrome, multiple myeloma/plasma cell neoplasm, mycosis fungoides, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, islet cell pancreatic cancer, parathyroid cancer, pheochromocytoma, pineoblastoma, pituitary tumor, pleuropulmonary blastoma, ureter transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Sezary syndrome, non-melanoma skin cancer, Merkel cell carcinoma, squamous cell carcinoma, testicular cancer, thymoma, gestational trophoblastic tumor, and Wilms' tumor.

### Claim 36 (depends on 33)

The method of claim 33, wherein the disease or condition is a hematological tumor.

### Claim 37 (depends on 36)

The method of claim 36, wherein the hematological tumor is selected from the group consisting of acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.

### Claim 38 (depends on 33)

The method of claim 33, wherein the disease or condition is selected from the group consisting of idiopathic pulmonary fibrosis, systemic sclerosis associated interstitial lung disease, myositis associated interstitial lung disease, systemic lupus erythematosus associated interstitial lung disease, rheumatoid arthritis, and associated interstitial lung disease.

### Claim 39 (depends on 33)

The method of claim 33, wherein the disease or condition is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis, and chronic kidney disease.

### Claim 40 (depends on 33)

The method of claim 33, wherein the disease or condition is selected from the group consisting of nonalcoholic steatohepatitis, primary biliary cholangitis, and primary sclerosing cholangitis.
